Category Archives: ALS Treatment

Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities. Sangamo CEO Sandy Macrae told us how his company is being cautious about the hype and finding ways to be financially viable in an emerging space. Cutting edge is, for once, a truly apt description when it comes to gene editing both because the field is pushing medicine into areas we might never have dreamed possible, and because these technologies involve literally cutting DNA at a specific point in the genome. Continue reading →

The new law grants ALS patients and families immediate access to the Social Security Disability Insurance benefits theyve earned. WASHINGTON, D.C., USA On Dec Continue reading →

Dec. 21, 2020 11:00 UTC NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (Aptorum Group or Aptorum), a biopharmaceutical company focused on novel technologies for the treatment of a variety of medical conditions including infectious diseases, announced that the company, through its wholly owned subsidiary Aptorum International Limited, has submitted a Clinical Trial Application (CTA) with the Public Health Agency of Canada (Health Canada) to conduct a Phase 1 clinical trial of ALS-4, an orally administered small molecule drug for the treatment of infections caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA). Continue reading →

Share This Article: Dr. Rick Greenberg talks about his identical twin brother David, who was diagnosed with ALS in 2014 and died Dec. 7, 2016 Continue reading →

Data Bridge Market Research Added A New Report on ALS Treatment Market That Provides A Comprehensive Review of This Industry with Respect to The Driving Forces Influencing The ALS Treatment Market Size. Continue reading →

NEW YORK, Dec. 21, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc. Continue reading →

Medicare Part A covers inpatient stays at a hospital or skilled nursing facility (SNF). Other areas of coverage include hospice and home healthcare. Continue reading →

19 Dec 2020 The anti-inflammatory medication masitinib met its primary endpoint in an Alzheimers disease trial, according to topline data announced December 16 by its sponsor, the Paris-based company AB Science. In the six-month Phase 2b/3 study of 718 AD patients, the drug appeared to halt cognitive decline, with the treatment group, on average, notching slight improvements on the ADAS-Cog. Continue reading →

Newly Launched JT's Angel Fund delivers emergency financial assistance to mid-Atlantic ALS families during pandemic. Managing this charitable fund is a deeply personal mission for everyone involved, including Josh's family, the Virginia Gentlemen Foundation, and the ALS Association's Virginia Chapter. Josh's father, Virginia Beach developer Bruce Thompson, along with non-profit group the Virginia Gentlemen Foundation, has raised over $30 million to fulfill Josh's vision of providing research funding for ALS and to build facilities for people with disabilities Continue reading →

When the coronavirus pandemic hit the in March, Lafayette-based VieMed Healthcare became a go-to source for much-needed ventilators. Hospitals, physicians and as many as 16 state governments reached out for ventilators when the surge first hit and ventilators were scarce. Company founders Casey Hoyt and Mike Moore helped clinicians and hospitals learn how to assemble and use the ventilators and made about 30 videos in 48 hours that taught clinicians how to use a home ventilator during peak surge periods when people were scrambling to help patients breathe. Continue reading →